NantHealth’s Liquid GPS™ technology shows promise in the monitoring of key biomarkers in metastatic colorectal cancer MUNICH and CULVER CITY,...
Research shows that while on immunotherapy, plasma levels of PD-L1 expression can be used in order to monitor clinical responses....
Molecular test allows for continuous, noninvasive monitoring and tumor profiling CHICAGO— June 2, 2018 – NantHealth, Inc., (NASDAQ: NH), a...